{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:37:12Z","timestamp":1793745432846,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT180417"],"award-info":[{"award-number":["PJT180417"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009779","name":"Bladder Cancer Advocacy Network","doi-asserted-by":"publisher","award":["N\/a"],"award-info":[{"award-number":["N\/a"]}],"id":[{"id":"10.13039\/100009779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69927-7","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:47:55Z","timestamp":1772167675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6471-6065","authenticated-orcid":false,"given":"David C.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-7656","authenticated-orcid":false,"given":"Andrew J.","family":"Murtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack V. W.","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vasquez-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Rostin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rebane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sch\u00f6nlau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Nikkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimira","family":"Alimohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daygen","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guliz","family":"Ozgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Parimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-1285","authenticated-orcid":false,"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-5787","authenticated-orcid":false,"given":"Paul","family":"Toren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8829-5979","authenticated-orcid":false,"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily Q.","family":"Bernales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Koudjanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskirat","family":"Atwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryndan","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Bismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0225-4173","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Merza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas I.","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3020-1420","authenticated-orcid":false,"given":"Alan","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-4497","authenticated-orcid":false,"given":"Corinne","family":"Maurice-Dror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-9026","authenticated-orcid":false,"given":"Matti","family":"Annala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-0908","authenticated-orcid":false,"given":"Gillian","family":"Vandekerkhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-0329","authenticated-orcid":false,"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1653-6929","authenticated-orcid":false,"given":"Bernhard J.","family":"Eigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"69927_CR1","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","volume":"64","author":"BWG van Rhijn","year":"2004","unstructured":"van Rhijn, B. W. G. et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 64, 1911\u20131914 (2004).","journal-title":"Cancer Res."},{"key":"69927_CR2","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/annonc\/mdw170","volume":"27","author":"D Pouessel","year":"2016","unstructured":"Pouessel, D. et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann. Oncol. 27, 1311\u20131316 (2016).","journal-title":"Ann. Oncol."},{"key":"69927_CR3","doi-asserted-by":"crossref","unstructured":"Knowles, M. A. FGFR3\u2014a central player in bladder cancer pathogenesis? Bladder Cancer 6 403\u2013423 (2020).","DOI":"10.3233\/BLC-200373"},{"key":"69927_CR4","first-page":"1","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Prim. 9, 1\u201321 (2023).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"69927_CR5","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961\u20131971 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69927_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/JCO.2025.43.5_suppl.662","volume":"43","author":"G Iyer","year":"2025","unstructured":"Iyer, G. et al. A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: initial results from FORAGER-1. J. Clin. Oncol. 43, 662\u2013662 (2025).","journal-title":"J. Clin. Oncol."},{"key":"69927_CR7","doi-asserted-by":"publisher","first-page":"114599","DOI":"10.1016\/j.ejca.2024.114599","volume":"211","author":"Y Loriot","year":"2024","unstructured":"Loriot, Y. et al. TYRA-300, an oral, FGFR3-selective inhibitor: preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1\/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations. Eur. J. Cancer 211, 114599 (2024). 72 (PB060).","journal-title":"Eur. J. Cancer"},{"key":"69927_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook, M. A. et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br. J. Cancer 124, 880\u2013892 (2021).","journal-title":"Br. J. Cancer"},{"key":"69927_CR9","doi-asserted-by":"publisher","first-page":"111859","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton, T. N. et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 41, 111859 (2022).","journal-title":"Cell Rep."},{"key":"69927_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.euo.2021.11.002","volume":"5","author":"JVW Bacon","year":"2022","unstructured":"Bacon, J. V. W. et al. Somatic features of response and relapse in non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin immunotherapy. Eur. Urol. Oncol. 5, 677\u2013686 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"69927_CR11","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"Guercio, B. J. et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin. Cancer Res. 29,\u00a04586\u20134595 (2023).","journal-title":"Clin. Cancer Res."},{"key":"69927_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.euo.2025.07.009","volume":"8","author":"N Matsubara","year":"2025","unstructured":"Matsubara, N. et al. Fibroblast growth factor receptor alteration testing for >3600 Patients with locally advanced\/metastatic urothelial cancer and non-muscle-invasive bladder cancer: an analysis of the Global ANNAR Biomarker Study. Eur. Urol. Oncol. 8,\u00a01558\u20131565 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"69927_CR13","doi-asserted-by":"crossref","unstructured":"Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat. Commun. 12, 184 (2021).","DOI":"10.1038\/s41467-020-20493-6"},{"key":"69927_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"Birkenkamp-Demtr\u00f6der, K. et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur. Urol. 73, 535\u2013540 (2018).","journal-title":"Eur. Urol."},{"key":"69927_CR15","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","volume":"23","author":"G Vandekerkhove","year":"2017","unstructured":"Vandekerkhove, G. et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin. Cancer Res. 23, 6487\u20136497 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69927_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen, E. et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur. Urol. 71, 961\u2013969 (2017).","journal-title":"Eur. Urol."},{"key":"69927_CR17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","volume":"29","author":"E Christensen","year":"2023","unstructured":"Christensen, E. et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin. Cancer Res. 29, 1582 (2023).","journal-title":"Clin. Cancer Res."},{"key":"69927_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca, N. M. et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat. Commun. 15, 1828 (2024).","journal-title":"Nat. Commun."},{"key":"69927_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","volume":"7","author":"SH Tolmeijer","year":"2024","unstructured":"Tolmeijer, S. H. et al. Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer. Eur. Urol. Oncol. 7, 282\u2013291 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"69927_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","volume":"68","author":"JP Sfakianos","year":"2015","unstructured":"Sfakianos, J. P. et al. Genomic characterization of upper tract urothelial carcinoma. Eur. Urol. 68, 970\u2013977 (2015).","journal-title":"Eur. Urol."},{"key":"69927_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","volume":"29","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. 29, 588\u2013592 (2023).","journal-title":"Nat. Med."},{"key":"69927_CR22","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1158\/1078-0432.CCR-24-3912","volume":"31","author":"G Vandekerkhove","year":"2025","unstructured":"Vandekerkhove, G. et al. ERBB2\/HER2 alterations in ctDNA and metachronous tissues of patients with metastatic urothelial cancer. Clin. Cancer Res 31, 3725\u20133741 (2025).","journal-title":"Clin. Cancer Res"},{"key":"69927_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","volume":"126","author":"KS Shohdy","year":"2022","unstructured":"Shohdy, K. S. et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br. J. Cancer 126, 430\u2013439 (2022).","journal-title":"Br. J. Cancer"},{"key":"69927_CR24","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","volume":"13","author":"F Facchinetti","year":"2023","unstructured":"Facchinetti, F. et al. Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer Discov. 13, 1998\u20132011 (2023).","journal-title":"Cancer Discov."},{"key":"69927_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113368","volume":"195","author":"C Helal","year":"2023","unstructured":"Helal, C. et al. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. Eur. J. Cancer 195, 113368 (2023).","journal-title":"Eur. J. Cancer"},{"key":"69927_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114186","volume":"207","author":"L Andersen","year":"2024","unstructured":"Andersen, L. et al. Exploring the biology of ctDNA release in colorectal cancer. Eur. J. Cancer 207, 114186 (2024).","journal-title":"Eur. J. Cancer"},{"key":"69927_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00654","volume":"8","author":"G Vandekerkhove","year":"2024","unstructured":"Vandekerkhove, G. et al. Toward informed selection and interpretation of clinical genomic tests in prostate cancer. JCO Precis Oncol. 8, e2300654 (2024).","journal-title":"JCO Precis Oncol."},{"key":"69927_CR28","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).","journal-title":"PLoS Med."},{"key":"69927_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7, 1006\u20131017 (2017).","journal-title":"Cancer Discov."},{"key":"69927_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7162","author":"GR Oxnard","year":"2016","unstructured":"Oxnard, G. R. et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non\u2013small-cell lung cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2016.66.7162 (2016).","journal-title":"J. Clin. Oncol."},{"key":"69927_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","volume":"83","author":"A Loehr","year":"2023","unstructured":"Loehr, A. et al. Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib. Eur. Urol. 83, 200\u2013209 (2023).","journal-title":"Eur. Urol."},{"key":"69927_CR32","doi-asserted-by":"publisher","first-page":"16737","DOI":"10.1021\/acs.jmedchem.4c01531","volume":"67","author":"RL Hudkins","year":"2024","unstructured":"Hudkins, R. L. et al. Discovery of TYRA-300: first oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia. J. Med Chem. 67, 16737\u201316756 (2024).","journal-title":"J. Med Chem."},{"key":"69927_CR33","doi-asserted-by":"publisher","first-page":"P141","DOI":"10.1158\/1535-7163.TARG-21-P141","volume":"20","author":"JA Ballard","year":"2021","unstructured":"Ballard, J. A. et al. Abstract P141: preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor. Mol. Cancer Ther. 20, P141\u2013P141 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"69927_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3233\/BLC-201517","volume":"7","author":"P Grivas","year":"2021","unstructured":"Grivas, P. et al. Spectrum of alterations in cell-free DNA of patients with advanced urothelial carcinoma. Bladder Cancer 7, 143\u2013148 (2021).","journal-title":"Bladder Cancer"},{"key":"69927_CR35","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750\u2013768 (2022).","journal-title":"Ann. Oncol."},{"key":"69927_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1200\/JCO.2019.37.7_suppl.420","volume":"37","author":"AE Santiago-Walker","year":"2019","unstructured":"Santiago-Walker, A. E. et al. Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC). J. Clin. Oncol. 37, 420\u2013420 (2019).","journal-title":"J. Clin. Oncol."},{"key":"69927_CR37","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).","journal-title":"J. Biomed. Inform."},{"key":"69927_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","volume":"5","author":"EW Warner","year":"2024","unstructured":"Warner, E. W. et al. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat. Cancer 5, 114\u2013130 (2024).","journal-title":"Nat. Cancer"},{"key":"69927_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts, C. et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608, 199\u2013208 (2022).","journal-title":"Nature"},{"key":"69927_CR40","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","volume":"29","author":"SH Tolmeijer","year":"2023","unstructured":"Tolmeijer, S. H. et al. Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29,\u00a02835\u20132844 (2023).","journal-title":"Clin. Cancer Res."},{"key":"69927_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.annonc.2025.10.1236","volume":"37","author":"T Virtanen","year":"2025","unstructured":"Virtanen, T. et al. Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer. Ann. Oncol.\u00a037,\u00a0388\u2013402\u00a0(2026).","journal-title":"Ann. Oncol."},{"key":"69927_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02423-x","volume":"22","author":"DL Cameron","year":"2021","unstructured":"Cameron, D. L. et al. GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. Genome Biol. 22, 202 (2021).","journal-title":"Genome Biol."},{"key":"69927_CR43","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1093\/bioinformatics\/bty304","volume":"34","author":"V Geoffroy","year":"2018","unstructured":"Geoffroy, V. et al. AnnotSV: an integrated tool for structural variations annotation. Bioinformatics 34, 3572\u20133574 (2018).","journal-title":"Bioinformatics"},{"key":"69927_CR44","doi-asserted-by":"publisher","unstructured":"Muller, D. C. et al. Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer. GitHub repository: wyatt-lab\/fgfr_ctdna_tissue https:\/\/doi.org\/10.5281\/zenodo.18158103 (2026).","DOI":"10.5281\/zenodo.18158103"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69927-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69927-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69927-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T22:02:11Z","timestamp":1775772131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69927-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69927"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69927-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C.M.: Honoraria\u2014EMD Serono; Travel, Accommodations, Expenses\u2014EMD Serono. A.J.M.: Honoraria\u2014EMD Serono; Travel, Accommodations, Expenses\u2014EMD Serono. L.N.: Honoraria\u2014Bayer; Ipsen; Janssen; Pfizer; Tersera; Consulting or Advisory Role\u2014Bayer; Eisai; Ipsen; Novartis; Pfizer; Research Funding - Bayer (Inst); Travel, Accommodations, Expenses\u2014Pfizer, Ipsen. P.T. has served on advisory boards and\/or received honoraria from Bayer, Astellas and has contract research agreements (via institution) with AstraZeneca and Janssen. E.W.: Honoraria\u2014EMD Serono; Travel, Accommodations, Expenses\u2014Eisai; Consulting or Advisory Role\u2014Bayer, Eisai, EMD Serono, Merck, Roche; Research Funding\u2014Lilly, Novartis, Merck. A.S. has served on advisory boards to Janssen. C.M.D.: Pfizer, Merck, Astra Zenca, Novartis, consulting\/advisory: Biomica Ltd, Merck, Pfizer and Eisai, Novartis, travel expenses: Janssen, GSK, Pfizer. G.V.: research funding from Gilead Sciences; travel expenses, honoraria and\/or advisory board roles from Gilead Sciences, Janssen, and EMD Serono. A.W.W. has served on advisory boards and\/or received honoraria from AstraZeneca, Astellas, Bayer, EMD Serono, Janssen, Merck, and Pfizer; and has contract research agreements (via institution) with ESSA Pharma, Tyra Biosciences, and Promontory Therapeutics. The remaining authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3263"}}